Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case report.

Case report

Describes an individual case.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease

Case report · Frontiers in Endocrinology · 2026

Original publication title

Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease

Sofya Ilmer; Parissa Salemi

Copyright © 2026 Ilmer and Salemi.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

This case report describes an 11-year-old male with Graves disease and pre-existing Mobitz type 1 second-degree atrioventricular (AV) block that progressed to complete heart block (CHB) one month prior to his diagnosis of Graves disease. He presented at age 9 years (January 2023) with weight loss, heat intolerance, and excessive sweating. Laboratory testing revealed: thyroid stimulating hormone (TSH) <0.01 uIU/mL, free thyroxine (FT4) 4.8 ng/dL, total thyroxine (T4) 16.7 µg/dL, and total triiodothyronine (T3) 334 ng/dL. He was treated with methimazole and was biochemically euthyroid within one month of treatment.

Despite becoming euthyroid, the CHB persisted. By April of 2023, his cardiologist recommended the implantation of a pacemaker, however the family opted for continued monitoring instead. Following his mother’s research into potential benefits of vitamin D in autoimmune thyroid disease, vitamin D3 supplementation 2500 IU daily was initiated in late October 2023. Three months later, his nighttime bradycardia resolved. A 12-lead ECG in April 2024 confirmed the resolution of CHB to first-degree AV block. No additional medications were used to treat his cardiac condition.

Patient remained stable with first-degree heart block while euthyroid on low dose methimazole. He continued vitamin D supplementation at 2000 IU daily. Peak TSH receptor antibody (TSHRab) and thyroid-stimulating immunoglobulin (TSI) values decreased following vitamin D3 initiation. Several proposed mechanisms may explain this observation, including vitamin D’s immunomodulatory effects on Graves disease, its cardioprotective properties, and its potential synergistic effect with methimazole in achieving better thyroid control. This case highlights a potential association between vitamin D supplementation and improved AV block in a pediatric patient with Graves disease, warranting further investigation into vitamin D’s role in managing cardiac manifestations of autoimmune thyroid disease.

Authors’ abstract

This case report describes an 11-year-old male with Graves disease and pre-existing Mobitz type 1 second-degree atrioventricular (AV) block that progressed to complete heart block (CHB) one month prior to his diagnosis of Graves disease. He presented at age 9 years (January 2023) with weight loss, heat intolerance, and excessive sweating. Laboratory testing revealed: thyroid stimulating hormone (TSH) <0.01 uIU/mL, free thyroxine (FT4) 4.8 ng/dL, total thyroxine (T4) 16.7 µg/dL, and total triiodothyronine (T3) 334 ng/dL. He was treated with methimazole and was biochemically euthyroid within one month of treatment.

Despite becoming euthyroid, the CHB persisted. By April of 2023, his cardiologist recommended the implantation of a pacemaker, however the family opted for continued monitoring instead. Following his mother’s research into potential benefits of vitamin D in autoimmune thyroid disease, vitamin D3 supplementation 2500 IU daily was initiated in late October 2023. Three months later, his nighttime bradycardia resolved. A 12-lead ECG in April 2024 confirmed the resolution of CHB to first-degree AV block. No additional medications were used to treat his cardiac condition.

Patient remained stable with first-degree heart block while euthyroid on low dose methimazole. He continued vitamin D supplementation at 2000 IU daily. Peak TSH receptor antibody (TSHRab) and thyroid-stimulating immunoglobulin (TSI) values decreased following vitamin D3 initiation. Several proposed mechanisms may explain this observation, including vitamin D’s immunomodulatory effects on Graves disease, its cardioprotective properties, and its potential synergistic effect with methimazole in achieving better thyroid control. This case highlights a potential association between vitamin D supplementation and improved AV block in a pediatric patient with Graves disease, warranting further investigation into vitamin D’s role in managing cardiac manifestations of autoimmune thyroid disease.

Publication and source details

Original title: Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease

Sofya Ilmer; Parissa Salemi

Frontiers in Endocrinology · 2026

* Correspondence: Parissa Salemi, psalemi@northwell.eduCopyright © 2026 Ilmer and Salemi.2026Ilmer and Salemihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:23:22.714135+00:00

DOI: 10.3389/fendo.2025.1680344 · PMC12827079